Key terms

About ELVN

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ELVN news

Today 2:25am ET Buy Rating Affirmed: Enliven Therapeutics’ ELVN-001 Shows Market Potential and Efficacy in Resistant Patients by TipRanks Apr 18 4:48pm ET Enliven files to sell 6.43M shares of common stock for holders by TipRanks Apr 18 1:10am ET Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS) by TipRanks Apr 13 3:28pm ET Short Report: Bears reduce exposure to Kohl’s as stock momentum fizzles by TipRanks Apr 11 6:35pm ET Strong Buy Rating for Enliven Therapeutics’ ELVN-001 Following Outstanding Phase 1 Results and Market Potential by TipRanks Apr 11 8:04am ET Enliven announces proof of concept data from Phase 1 trial of ELVN-001 by TipRanks Apr 11 7:45am ET Enliven to hold a conference call by TipRanks Apr 11 4:55am ET Enliven to hold a conference call by TipRanks Mar 28 4:15pm ET Enliven to share initial proof of concept data from ELVN-001 Phase 1 trial by TipRanks Mar 20 7:30am ET Analysts’ Top Healthcare Picks: Enliven Therapeutics (ELVN), Alphatec Holdings (ATEC) by TipRanks Mar 19 9:02am ET Enliven Therapeutics Secures $90M for Clinical Research Expansion by TipRanks Mar 19 8:40am ET Enliven announces pipeline updates by TipRanks Mar 19 8:38am ET Enliven announces $90M private placement financing by TipRanks Mar 15 2:55pm ET Strong Buy Rating for Enliven Therapeutics Backed by Innovative Drug Candidates and Financial Stability by TipRanks Mar 14 9:45pm ET TD Cowen Sticks to Their Buy Rating for Enliven Therapeutics (ELVN) by TipRanks Mar 14 4:23pm ET Enliven reports Q4 EPS (47c), consensus (54c) by TipRanks

No recent press releases are available for ELVN

ELVN Financials

1-year income & revenue

Key terms

ELVN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ELVN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Meta headquarters pictured on February 02, 2023 in Menlo Park, California.
Justin Sullivan/Getty Images
Meta’s stock plunges 15% on ‘aggressive’ AI spending plans
GettyImages-1159438448 copy.jpg
Lyndon Stratford/iStockphoto/Getty Images
Americans are falling behind on their payments
The logo of Swiss bank UBS is seen at the company's headquarters in Zurich, Switzerland February 10, 2015. REUTERS/Arnd Wiegmann/File Photo
Arnd Wiegmann/Reuters
Switzerland says UBS may need more cash. The bank is fuming
Jamie Dimon, Chairman and Chief Executive officer (CEO) of JPMorgan Chase & Co. (JPM) speaks to the Economic Club of New York in Manhattan in New York City, U.S., April 23, 2024. REUTERS/Mike Segar
Mike Segar/Reuters
Jamie Dimon fears for the future of the free world and US debt